[breadcrumb_custom]

How To Know If Foghorn Therapeutics Inc (NASDAQ:FHTX) Is Expensive At $4.85.

In last trading session, Foghorn Therapeutics Inc (NASDAQ:FHTX) saw 1.67 million shares changing hands with its beta currently measuring 2.64. Company’s recent per share price level of $4.85 trading at $1.73 or 55.45% at ring of the bell on the day assigns it a market valuation of $204.77M. That closing price of FHTX’s stock is at a discount of -105.57% from its 52-week high price of $9.97 and is indicating a premium of 44.33% from its 52-week low price of $2.70. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.19 million shares which gives us an average trading volume of 108.26K if we extend that period to 3-months.

Foghorn Therapeutics Inc (NASDAQ:FHTX) trade information

Upright in the green during last session for gaining 55.45%, in the last five days FHTX remained trading in the green while hitting it’s week-highest on Thursday, 02/08/24 when the stock touched $4.85 price level, adding 16.23% to its value on the day. Foghorn Therapeutics Inc’s shares saw a change of -24.81% in year-to-date performance and have moved 60.07% in past 5-day. Foghorn Therapeutics Inc (NASDAQ:FHTX) showed a performance of -11.01% in past 30-days. Number of shares sold short was 0.91 million shares which calculate 9.67 days to cover the short interests.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Foghorn Therapeutics Inc (FHTX) estimates and forecasts

Statistics highlight that Foghorn Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -48.62% of value to its shares in past 6 months, showing an annual growth rate of 6.49% while that of industry is 11.30. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to decrease by -10.10% in the current quarter and calculating 5.50% increase in the next quarter. This year revenue growth is estimated to rise 68.80% from the last financial year’s standing.

5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $4.62 million for the same. And 5 analysts are in estimates of company making revenue of $6.88 million in the next quarter that will end on Mar 2024. Company posted $4.18 million and $5.04 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 10.40% while estimating it to be 36.50% for the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -38.31% during past 5 years.

FHTX Dividends

Foghorn Therapeutics Inc is more likely to be releasing its next quarterly report between March 09 and March 13 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Foghorn Therapeutics Inc (NASDAQ:FHTX)’s Major holders

Insiders are in possession of 25.13% of company’s total shares while institution are holding 65.49 percent of that, with stock having share float percentage of 87.47%. Investors also watch the number of corporate investors in a company very closely, which is 65.49% institutions for Foghorn Therapeutics Inc that are currently holding shares of the company. Flagship Pioneering Inc. is the top institutional holder at FHTX for having 12.67 million shares of worth $89.23 million. And as of Jun 29, 2023, it was holding 30.28% of the company’s outstanding shares.

The second largest institutional holder is FMR, LLC, which was holding about 2.91 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 6.95% of outstanding shares, having a total worth of $20.47 million.

On the other hand, Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Aug 30, 2023, the former fund manager was holding 0.92 million shares of worth $6.96 million or 2.20% of the total outstanding shares. The later fund manager was in possession of 0.55 million shares on Jun 29, 2023, making its stake of worth around $3.88 million in the company or a holder of 1.32% of company’s stock.

On Key

Related Posts